1,755
Views
0
CrossRef citations to date
0
Altmetric
Oncology

An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States

ORCID Icon, , , , , , , & ORCID Icon show all
Pages 77-83 | Received 24 Oct 2023, Accepted 30 Nov 2023, Published online: 19 Dec 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.